ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005354

chronic hepatitis C virus infection

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. chronic hepatitis C virus infection. Diseases, record MONDO_0005354. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005354

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
chronic hepatitis C virus infection
Open Targets
Open Targets ID
MONDO_0005354
Open Targets
Other names
Chronic Hepatitis C infection, chronic Hepatitis C, chronic hepatitis C with hepatic coma, chronic type C viral hepatitis, chronic viral hepatitis C, hepatitis C infection, chronic, hepatitis C, chronic
Open Targets
MeSH
D019698
MeSH
Highest stage of its drugs
Approval, for 32 of its 92 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA
Open Targets

Drugs92

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
RIBAVIRINCHEMBL1643Small moleculeApprovalDailyMed and PMDA178146146Drugs and targets
PEGINTERFERON ALFA-2ACHEMBL1201560ProteinApprovalDailyMed and EMA Human Drugs747264Drugs and targets
PEGINTERFERON ALFA-2BCHEMBL1201561ProteinApprovalDailyMed and PMDA393428Drugs and targets
SOFOSBUVIRCHEMBL1259059Small moleculeApprovalDailyMed, EMA Human Drugs, FDA and PMDA463333Drugs and targets
DACLATASVIRCHEMBL2023898Small moleculeApprovalEMA Human Drugs, at withdrawal272626Drugs and targets
RITONAVIRCHEMBL163Small moleculeApprovalDailyMed and PMDA262323Drugs and targets
OMBITASVIRCHEMBL3127326Small moleculeApprovalDailyMed171515Drugs and targets
LEDIPASVIRCHEMBL2374220Small moleculeApprovalDailyMed and PMDA171414Drugs and targets
PARITAPREVIRCHEMBL3391662Small moleculeApprovalDailyMed161414Drugs and targets
INTERFERON ALFA-2BCHEMBL1201558ProteinApprovalFDA16133Drugs and targets

1 to 10 of 92

See all 92 drugs

Targets89

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
IFNAR1Interferon alpha/beta receptor7Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulatorApprovalhttps://conductscience.org/library/genes/3454Drugs and targets
IFNAR2Interferon alpha/beta receptor7Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulatorApprovalhttps://conductscience.org/library/genes/3455Drugs and targets
MPLThrombopoietin receptor3Thrombopoietin receptor agonistApprovalhttps://conductscience.org/library/genes/4352Drugs and targets
AGTR1Type-1 angiotensin II receptor2Type-1 angiotensin II receptor antagonistPhase 3https://conductscience.org/library/genes/185Drugs and targets
IMPDH1Inosine-5'-monophosphate dehydrogenase 12Inosine-5'-monophosphate dehydrogenase 1 inhibitorApprovalhttps://conductscience.org/library/genes/3614Drugs and targets
ACEAngiotensin-converting enzyme1Angiotensin-converting enzyme inhibitorPhase 3https://conductscience.org/library/genes/1636Drugs and targets
COXFA4Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorPhase 2https://conductscience.org/library/genes/4697Drugs and targets
COXFA4L2Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorPhase 2https://conductscience.org/library/genes/56901Drugs and targets
CYP3A4Cytochrome P450 3A1Cytochrome P450 3A inhibitorApprovalhttps://conductscience.org/library/genes/1576Drugs and targets
CYP3A43Cytochrome P450 3A1Cytochrome P450 3A inhibitorApprovalhttps://conductscience.org/library/genes/64816Drugs and targets

1 to 10 of 89

See all 89 targets

Trials221

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT02106156
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)
10,2282016-09-23Chronic Hepatitis CPEGINTERFERON ALFA-2A, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01447446An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C4,4422017-03-30Hepatitis C, ChronicBOCEPREVIR, INTERFERON ALFA-2A, INTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIRIts record names the diseaseClinicalTrials.gov
NCT02292706A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection1,6092023-10-04Hepatitis C Virus InfectionLEDIPASVIR, RIBAVIRIN, SOFOSBUVIR, VELPATASVIR, VOXILAPREVIRIts record names the diseaseClinicalTrials.gov
NCT00077636ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.Phase 41,4692016-01-21Hepatitis C, ChronicPEGINTERFERON ALFA-2A, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01429792A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)Phase 41,0132018-10-23Hepatitis C, ChronicPEGINTERFERON ALFA-2A, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01098097Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)9632012-11-20Hepatitis C, ChronicRIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01598090Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirPhase 38812019-05-21Hepatitis C VirusPEGINTERFERON LAMBDA-1A, RIBAVIRIN, TELAPREVIRIts record names the diseaseClinicalTrials.gov
NCT01485991
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase 37712015-04-10Hepatitis CPEGINTERFERON ALFA-2A, RIBAVIRIN, SIMEPREVIRIts record names the diseaseClinicalTrials.gov
NCT00423670Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)Phase 27652011-06-15Chronic Hepatitis CBOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT02557646An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C6972016-02-10Hepatitis C, ChronicPEGINTERFERON ALFA-2A, RIBAVIRINIts record names the diseaseClinicalTrials.gov

1 to 10 of 221

See all 221 trials

Comparisons in its trials68

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks vs PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks: serious adverse events34 of 73147 of 7281,459NCT00077636Trial comparisons
Simeprevir+Placebo+Peginterferon Alfa-2a+Ribavirin vs Telaprevir+Placebo+Peginterferon Alfa-2a+Ribavirin: serious adverse events22 of 37954 of 384763NCT01485991Trial comparisons
Placebo+Antiviral Therapy: DB Phase vs Eltrombopag+Antiviral Therapy: DB Phase: Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase129 of 232184 of 450682NCT00516321Trial comparisons
Placebo+Antiviral Therapy: DB Phase vs Eltrombopag+Antiviral Therapy: DB Phase: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase33 of 232104 of 450682NCT00516321Trial comparisons
Arm 3 and Arm 5. PEG + RBV + BOC (From Wk 4) vs Arm 2 and Arm 4. PEG + RBV + BOC: Number of Participants With SVR Based on a 4-week lead-in Treatment With PegIntron and Ribavirin135 of 206127 of 210416NCT00423670Trial comparisons
Arm 4 and Arm 5. PEG + RBV + BOC (48 Weeks) vs Arm 2 and Arm 3. PEG + RBV + BOC (28 Weeks): Number of Participants With SVR Based on Duration of Boceprevir Treatment146 of 206116 of 210416NCT00423670Trial comparisons
Standard Monitoring Schedule vs Simplified Monitoring Schedule: Severe/Life Threatening Adverse Events (Safety Outcome)1 of 1272 of 253380NCT03117569Trial comparisons
Standard Monitoring Schedule vs Simplified Monitoring Schedule: Undetectable HCV RNA (ITT Population)121 of 127233 of 253380NCT03117569Trial comparisons
Standard Monitoring Schedule vs Simplified Monitoring Schedule: deaths from any cause0 of 1271 of 253380NCT03117569Trial comparisons
Standard Monitoring Schedule vs Simplified Monitoring Schedule: serious adverse events0 of 1273 of 253380NCT03117569Trial comparisons

1 to 10 of 68

See all 68 comparisons in its trials

Papers from its trials132

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
29152828RESULT1PubMed
28193518RESULT1PubMed
27873094RESULT1PubMed
27720838RESULT1PubMed
26962399RESULT1PubMed
26462288RESULT1PubMed
26321288RESULT1PubMed
25909356RESULT1PubMed
25086286RESULT1PubMed
24251930RESULT1PubMed

1 to 10 of 132

See all 132 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005354

GET https://conductscience.org/api/diseases/v1/MONDO_0005354/drugs?page=2

API referenceFor AI assistants